Use of genetic variants to predict opioid use disorder risk may lead to inaccurate results

Candidate genetic variants included in a genetic risk algorithm may not meet standards of reasonable clinical efficacy in identifying opioid use disorder risk, according to a study published in JAMA Network Open.
“The FDA recently gave premarketing approval to an algorithm (AvertD, SOLVD Health) that incorporates 15 single nucleotide variants to predict opioid use disorder (OUD) risk,” Christal N. Davis, PhD, postdoctoral fellow at the Corporal Michael J. Crescenz Department of Veterans Affairs Medical Center in Philadelphia, and colleagues wrote. “The package insert for the

Candidate genetic variants included in a genetic risk algorithm may not meet standards of reasonable clinical efficacy in identifying opioid use disorder risk, according to a study published in JAMA Network Open.
“The FDA recently gave premarketing approval to an algorithm (AvertD, SOLVD Health) that incorporates 15 single nucleotide variants to predict opioid use disorder (OUD) risk,” Christal N. Davis, PhD, postdoctoral fellow at the Corporal Michael J. Crescenz Department of Veterans Affairs Medical Center in Philadelphia, and colleagues wrote. “The package insert for the